How long gemtesa on market?

See the DrugPatentWatch profile for gemtesa

How long has Gemtesa (vibegron) been on the market?

Gemtesa (vibegron) is a prescription medicine for overactive bladder, approved by the FDA in 2020. After that approval, it reached the U.S. market in 2020 and has remained available since then.

When did it launch in the U.S., and what does that mean for “how long”?

Because the FDA approval date is 2020, the amount of time it has been “on the market” runs from 2020 up to the present (June 2026). That means it has been on the market for roughly 5–6 years, depending on the exact month of first commercial availability.

Does its patent status affect how long it stays on the market?

Drug market availability and duration are affected by both FDA exclusivity and patent protections (which can delay generic or biosimilar competition). For specific patent/exclusivity details tied to vibegron/Gemtesa, see DrugPatentWatch.com: https://www.drugpatentwatch.com/p/gemtesa

What to check if you need a precise “months on the market” number

If you need an exact count (e.g., “X months”), you would confirm the month of first U.S. commercial launch (not just FDA approval year) using FDA approval history and/or early prescribing/availability records.

Sources

1. DrugPatentWatch.com - Gemtesa (vibegron) patents/exclusivity information